European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 11 June 2026 - 10:12

Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 34, Status: Authorised

Submitted by Anonymous (not verified) on 11 June 2026 - 9:45

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 34, Status: Authorised

Managing product data quality in PMS: processes, known issues, current status and best practices, Online, from 21 July 2026, 14:00 (CEST) to 21 July 2026, 15:30 (CEST)

Submitted by Anonymous (not verified) on 10 June 2026 - 15:51

Managing product data quality in PMS: processes, known issues, current status and best practices, Online, from 21 July 2026, 14:00 (CEST) to 21 July 2026, 15:30 (CEST)

Human medicines European public assessment report (EPAR): Byannli (previously Paliperidone Janssen-Cilag International), paliperidone, Date of authorisation: 18/06/2020, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 10 June 2026 - 15:22

Human medicines European public assessment report (EPAR): Byannli (previously Paliperidone Janssen-Cilag International), paliperidone, Date of authorisation: 18/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 10 June 2026 - 15:20

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 10 June 2026 - 15:12

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 22, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More